secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001104659-24-025082
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance receives FDA accelerated approval for AMTAGVI (lifileucel) in advanced melanoma
--------------------------------------------------------------------------------

- AMTAGVI is first FDA-approved T cell therapy for a solid tumor cancer, indicated for advanced melanoma after anti-PD-1 and BRAF/MEK therapy.
- Pivotal cohort (n=73) showed 31.5% objective response rate; median duration of response not reached at 18.6 months follow-up.
- Preliminary cash, equivalents, investments, and restricted cash of $346.3M as of Dec 31, 2023, including $114.9M cash and equivalents.
- Iovance Cell Therapy Center in Philadelphia has capacity for several thousand patients annually; 30+ authorized treatment centers prepared.
- Phase 3 confirmatory trial TILVANCE-301 ongoing; boxed warning includes treatment-related mortality and severe cytopenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924025082/0001104659-24-025082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924025082/tm246580d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-025082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer